Phospho-EZH2 (Thr416) Antibody - #AF3585

(1)   (6)  
製品: Phospho-EZH2 (Thr416) Antibody
カタログ: AF3585
タンパク質の説明: Rabbit polyclonal antibody to Phospho-EZH2 (Thr416)
アプリケーション: IHC IF/ICC
反応性: Human, Mouse, Rat
分子量: 85kD, 100kD; 85kD(Calculated).
ユニプロット: Q15910
RRID: AB_2846899

類似製品を見る>>

   サイズ 価格 在庫状況
 100ul $350 在庫あり
 200ul $450 在庫あり

リードタイム: 当日配達

For pricing and ordering contact:
お問い合わせ先
関連ダウンロード
MSDS
説明書
COA
プロトコル
WB Handbook
IHC Protocol
IF/ICC Protocol

製品説明

ソース:
Rabbit
アプリケーション:
IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

反応性:
Human,Mouse,Rat
クローナリティ:
Polyclonal
特異性:
Phospho-EZH2 (Thr416) Antibody detects endogenous levels of EZH2 only when phosphorylated at Thr416.
RRID:
AB_2846899
引用形式: Affinity Biosciences Cat# AF3585, RRID:AB_2846899.
コンジュゲート:
Unconjugated.
精製:
The antibody is from purified rabbit serum by affinity purification via sequential chromatography on phospho-peptide and non-phospho-peptide affinity columns.
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
別名:

折りたたみ／展開

Enhancer of zeste 2; enhancer of zeste 2 polycomb repressive complex 2 subunit; Enhancer of zeste homolog 2 (Drosophila); Enhancer of zeste homolog 2; Enhancer of zeste, Drosophila, homolog 2; ENX 1; Enx 1h; ENX-1; ENX1; Enx1h; EZH 2; EZH1; EZH2; EZH2_HUMAN; EZH2b; Histone-lysine N-methyltransferase EZH2; KMT 6; KMT6; KMT6A; Lysine N-methyltransferase 6; MGC9169; WVS; WVS2;

免疫原

免疫原:

A synthesized peptide derived from human EZH2 around the phosphorylation site of Thr416.

Uniprot:

Q15910(EZH2_HUMAN) >>Visit HPA database.

遺伝子(ID):
EZH2(2146)
発現特異性:
Q15910 EZH2_HUMAN:

Expressed in many tissues. Overexpressed in numerous tumor types including carcinomas of the breast, colon, larynx, lymphoma and testis.

タンパク質配列:
MGQTGKKSEKGPVCWRKRVKSEYMRLRQLKRFRRADEVKSMFSSNRQKILERTEILNQEWKQRRIQPVHILTSVSSLRGTRECSVTSDLDFPTQVIPLKTLNAVASVPIMYSWSPLQQNFMVEDETVLHNIPYMGDEVLDQDGTFIEELIKNYDGKVHGDRECGFINDEIFVELVNALGQYNDDDDDDDGDDPEEREEKQKDLEDHRDDKESRPPRKFPSDKIFEAISSMFPDKGTAEELKEKYKELTEQQLPGALPPECTPNIDGPNAKSVQREQSLHSFHTLFCRRCFKYDCFLHPFHATPNTYKRKNTETALDNKPCGPQCYQHLEGAKEFAAALTAERIKTPPKRPGGRRRGRLPNNSSRPSTPTINVLESKDTDSDREAGTETGGENNDKEEEEKKDETSSSSEANSRCQTPIKMKPNIEPPENVEWSGAEASMFRVLIGTYYDNFCAIARLIGTKTCRQVYEFRVKESSIIAPAPAEDVDTPPRKKKRKHRLWAAHCRKIQLKKDGSSNHVYNYQPCDHPRQPCDSSCPCVIAQNFCEKFCQCSSECQNRFPGCRCKAQCNTKQCPCYLAVRECDPDLCLTCGAADHWDSKNVSCKNCSIQRGSKKHLLLAPSDVAGWGIFIKDPVQKNEFISEYCGEIISQDEADRRGKVYDKYMCSFLFNLNNDFVVDATRKGNKIRFANHSVNPNCYAKVMMVNGDHRIGIFAKRAIQTGEELFFDYRYSQADALKYVGIEREMEIP

PTMs - Q15910 基板として

Site PTM Type Enzyme
K7 Ubiquitination
S8 Phosphorylation
K10 Ubiquitination
S21 Phosphorylation P31749 (AKT1)
Y23 Phosphorylation
K39 Ubiquitination
K61 Ubiquitination
S75 O-Glycosylation
S76 O-Glycosylation
S76 Phosphorylation
S212 Phosphorylation
S220 Phosphorylation
K234 Acetylation
K234 Ubiquitination
Y244 Phosphorylation
T261 Phosphorylation
S277 Phosphorylation
T302 Phosphorylation
T305 Phosphorylation
T311 Phosphorylation
K318 Ubiquitination
T339 Phosphorylation
T345 Phosphorylation P24941 (CDK2) , P06493 (CDK1)
K348 Acetylation
S362 Phosphorylation
S363 Phosphorylation P49841 (GSK3B)
S366 Phosphorylation
T367 Phosphorylation P49841 (GSK3B) , Q16539 (MAPK14)
T369 Phosphorylation
S375 Phosphorylation
S380 Phosphorylation
T388 Phosphorylation
S405 Phosphorylation
S406 Phosphorylation
S408 Phosphorylation
S412 Phosphorylation
T416 Phosphorylation P24941 (CDK2)
T460 Phosphorylation
K461 Ubiquitination
K472 Ubiquitination
S474 Phosphorylation
S475 Phosphorylation
T487 Phosphorylation P06493 (CDK1)
K505 Methylation
K509 Methylation
K510 Methylation
K569 Ubiquitination
K597 Ubiquitination
K602 Ubiquitination
K629 Ubiquitination
K634 Ubiquitination
Y641 Phosphorylation O60674 (JAK2)
S690 Phosphorylation
Y696 Phosphorylation
K713 Ubiquitination
T718 Phosphorylation
S729 Phosphorylation
K735 Methylation
K735 Ubiquitination

研究背景

機能:

Polycomb group (PcG) protein. Catalytic subunit of the PRC2/EED-EZH2 complex, which methylates 'Lys-9' (H3K9me) and 'Lys-27' (H3K27me) of histone H3, leading to transcriptional repression of the affected target gene. Able to mono-, di- and trimethylate 'Lys-27' of histone H3 to form H3K27me1, H3K27me2 and H3K27me3, respectively. Displays a preference for substrates with less methylation, loses activity when progressively more methyl groups are incorporated into H3K27, H3K27me0 > H3K27me1 > H3K27me2. Compared to EZH1-containing complexes, it is more abundant in embryonic stem cells and plays a major role in forming H3K27me3, which is required for embryonic stem cell identity and proper differentiation. The PRC2/EED-EZH2 complex may also serve as a recruiting platform for DNA methyltransferases, thereby linking two epigenetic repression systems. Genes repressed by the PRC2/EED-EZH2 complex include HOXC8, HOXA9, MYT1, CDKN2A and retinoic acid target genes. EZH2 can also methylate non-histone proteins such as the transcription factor GATA4 and the nuclear receptor RORA. Regulates the circadian clock via histone methylation at the promoter of the circadian genes. Essential for the CRY1/2-mediated repression of the transcriptional activation of PER1/2 by the CLOCK-ARNTL/BMAL1 heterodimer; involved in the di and trimethylation of 'Lys-27' of histone H3 on PER1/2 promoters which is necessary for the CRY1/2 proteins to inhibit transcription.

PTMs:

Phosphorylated by AKT1. Phosphorylation by AKT1 reduces methyltransferase activity. Phosphorylation at Thr-345 by CDK1 and CDK2 promotes maintenance of H3K27me3 levels at EZH2-target loci, thus leading to epigenetic gene silencing.

Sumoylated.

Glycosylated: O-GlcNAcylation at Ser-75 by OGT increases stability of EZH2 and facilitates the formation of H3K27me3 by the PRC2/EED-EZH2 complex.

細胞の位置付け:

Nucleus.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
組織特異性:

Expressed in many tissues. Overexpressed in numerous tumor types including carcinomas of the breast, colon, larynx, lymphoma and testis.

サブユニット構造:

Binds ATRX via the SET domain (Probable). Component of the PRC2/EED-EZH2 complex, which includes EED, EZH2, SUZ12, RBBP4 and RBBP7 and possibly AEBP2. The minimum components required for methyltransferase activity of the PRC2/EED-EZH2 complex are EED, EZH2 and SUZ12. The PRC2 complex may also interact with DNMT1, DNMT3A, DNMT3B and PHF1 via the EZH2 subunit and with SIRT1 via the SUZ12 subunit. Interacts with HDAC1 and HDAC2. Interacts with PRAME. Interacts with CDYL. Interacts with CLOCK, ARNTL/BMAL1 and CRY1 (By similarity). Interacts with DNMT3L; the interaction is direct (By similarity). Interacts with EZHIP; the interaction blocks EZH2 methyltransferase activity.

タンパク質ファミリー:

Belongs to the class V-like SAM-binding methyltransferase superfamily. Histone-lysine methyltransferase family. EZ subfamily.

研究領域

· Human Diseases > Cancers: Overview > MicroRNAs in cancer.

· Metabolism > Amino acid metabolism > Lysine degradation.

参考文献

1). Activation of Bivalent Gene POU4F1 Promotes and Maintains Basal-like Breast Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024 (PubMed: 38491910) [IF=15.1]

Application: WB    Species: Human    Sample: MDA‐MB‐231 and BT549 cells

Figure 5 POU4F1 repressed ERα expression through CDK2/EZH2 axis. A) ChIP‐qPCR analysis of the enrichment of POU4F1 at the promoter of ESR1 in MDA‐MB‐231 and BT549 cells. B,C) Indicated protein and mRNA expression in MDA‐MB‐231 and BT549 transfected with POU4F1 siRNAs and control siRNA. D, E) ChIP‐qPCR analysis of the enrichment of EZH2 and H3K27me3 at the promoter of ESR1 in MDA‐MB‐231 treated with DMSO, 100 nM SNS‐032 and 25 nM Dinaciclib D) and 5 µM GSK126 and 10 µM EPZ‐6438 E) for 72 h. F,G) The mRNA expression of ESR1 and its downstream genes in MDA‐MB‐231 cells treated with DMSO, 100 nM SNS‐032 and 25 nM Dinaciclib F) and 5 µM GSK126 and 10 µM EPZ‐6438 G) for 72 h. H) ChIP‐qPCR analysis of the enrichment of EZH2 and H3K27me3 at the promoter of ESR1 in POU4F1‐KO MDA‐MB‐231 cells. I) Western blotting showing the expression of indicated protein after rescue with CDK2, EZH2 and POU4F1 plasmid in POU4F1‐KO MDA‐MB‐231 cells. Data were presented as mean ± S.D., n = 3 A, B, D‐H). ns, no significance, *P < 0.05, **P < 0.01, ***P < 0.001 compared with IgG A),siCtrl B) and DMSO F,G) by two‐tailed Student's t‐test A) and two‐tailed one‐way ANOVA and Dunnett's B,F,G) or Bonferroni multiple‐comparisons test.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.